Clinical TopicsWeb Exclusives
fda treatment eosinophilic granulomatosis polyangiitis autoimmune disease vasculitis therapy approve stamp

FDA approves new treatment for eosinophilic granulomatosis with polyangiitis

On Dec. 12, the U.S. Food and Drug Administration (FDA) approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis. This new indication if the first FDA-approved therapy for EGPA.

Read more via Fda.gov.

Poll

Recent Posts